Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

BACKGROUND: Approximately 75% of objective responses to anti–programmed death 1 (PD-1) therapy in patients with melanoma are durable, lasting for years, but delayed relapses have been noted long after initial objective tumor regression despite continuous therapy. Mechanisms of immune escape in this...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:N Engl J Med
Prif Awduron: Zaretsky, Jesse M., Garcia-Diaz, Angel, Shin, Daniel S., Escuin-Ordinas, Helena, Hugo, Willy, Hu-Lieskovan, Siwen, Torrejon, Davis Y., Abril-Rodriguez, Gabriel, Sandoval, Salemiz, Barthly, Lucas, Saco, Justin, Moreno, Blanca Homet, Mezzadra, Riccardo, Chmielowski, Bartosz, Ruchalski, Kathleen, Shintaku, I. Peter, Sanchez, Phillip J., Puig-Saus, Cristina, Cherry, Grace, Seja, Elizabeth, Kong, Xiangju, Pang, Jia, Berent-Maoz, Beata, Comin-Anduix, Begoña, Graeber, Thomas G., Tumeh, Paul C., Schumacher, Ton N.M., Lo, Roger S., Ribas, Antoni
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2016
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5007206/
https://ncbi.nlm.nih.gov/pubmed/27433843
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1604958
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg